Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease

Area of Science:

• Cardiovascular Science
• Epigenetics
• Molecular Biology

Background:

• Current treatments for atherosclerosis and restenosis show limited efficacy due to disease heterogeneity and incomplete understanding of underlying mechanisms.
• Epigenetic mechanisms, including histone acetylation and DNA methylation, regulate gene expression without altering DNA sequence, influencing cellular processes.
• These epigenetic processes are implicated in extracellular matrix formation, inflammation, and proliferation, all critical in cardiovascular pathologies.

Purpose of the Study:

• To review the role of epigenetic regulators in the pathogenesis of atherosclerosis and restenosis.
• To highlight the potential of targeting epigenetic modifications for novel cardiovascular disease therapies.

Main Methods:

• Review of current literature on epigenetic mechanisms in cardiovascular diseases.
• Analysis of the role of histone acetylating and deacetylating enzymes in disease development.
• Examination of the reversibility of epigenetic alterations for therapeutic potential.

Main Results:

• Epigenetic regulators, specifically those controlling histone acetylation and deacetylation, are significantly involved in the development of atherosclerosis and restenosis.
• Alterations in chromatin structure mediated by these epigenetic factors contribute to disease pathogenesis.
• The reversible nature of these epigenetic modifications suggests they are druggable targets.

Conclusions:

• Epigenetic modifications are crucial contributors to the pathogenesis of atherosclerosis and restenosis.
• Pharmacological interventions targeting epigenetic regulators represent a potential new avenue for managing cardiovascular diseases.
• Further research into epigenetic therapies could lead to improved treatment outcomes for patients with these conditions.